

Strategic Plan 2022-2025



Sue Millman CEO Ataxia UK









Mission

We urgently want treatments and cure.

We fund and promote research with the aim of bringing this about; until this is achieved, we will do all we can to provide support to people affected by ataxia, and improve the quality of treatment and care they receive, to enable them to have the highest possible quality of life.





Plan Objectives



- Consistently maximise the impact of research activity leading to treatments and cures
- Enable greater access to services aimed at improving wellbeing & financial circumstances
- Improve access to specialist, integrated care (including mental health care), treatments and drugs for the ataxias
- Faster, accurate diagnosis





Research Activities

- Grants for Scientific/Medical Research
- Patient Advocacy
 - Research & drug development consortia (Global and European)
 - Pharmaceuticals
 - UK Policy and Regulation
 - Government Research/Biosciences policies
 - NHS/NICE/MHRA –eg drug approval processes Omaveloxolone
- Dissemination of ataxia research/information/patient perspectives
 - linternational Congress for Ataxia Rresearch







Funding Research Activities

- Friends & Supporters gifts/fundraising
- Commissioned by others
 - o DRPLA
 - AT Society
 - Euro-ataxia patient advocacy
 - Pharma
- Partnerships in funding medical research
 - Coeliac UK
 - Other ataxia patient groups e.g. FARA, NAF
- Funded patient advocacy roles in research consortia
- Sponsorship
- Grants from Trusts/Foundations







Peer Support & Volunteering



Local and online
Branches &
Support Groups



Online
Activities &
Information
Sessions







Friends Connect



Helpline Information Advice & Advocacy




Advice & Advocacy
































GET INVOLVED

HEALTHCARE PROFESSIONALS

Donate Now

ABOUT ATAXIA UK


WHAT IS ATAXIA?

Website Information









CONFERENCE

Information



All About Mobility Aids

(and ataxia)





All About Wheelchairs (and ataxia)



All About.

Please send us your ideas

All About Travel (and ataxia)



Treatment and Care





Revise & publish new Medical Guidelines




Online therapies





Develop counselling partnerships





Treatment & Care





















Treatment & Care: Influencing Policy

- Covid 19 early access to vaccines
- Ataxia treatment pathway NNAG
- UK Rare Diseases Framework
 - Virtual appointment protocols
 - Quality Standards
 - Genetic Testing







Income £1,575K 2021-22 (£1.905k 2020-21)

Donations £858K 2021-22

(£1,278k 2020-21) Legacies £258K 2021-22

(£188k 2020-21)

Fundraising £240K 2021-22

(£226k 2020-21)

Lottery £89K

Childlife £80K

Other £50K





Expenditure £1,341K 2021-22 (£3,006k 2020-

Research Activities £501K Care Services £331K Raising Funds £340K

Raising Awareness £105K Governance £64K





Reserves levels at year end

	2022 (£K)	2021 (£K)
General funds	570	590
Designated funds	154	8
Total unrestricted funds	724	598
Restricted research funds	(951)	(1,065)
Restricted services funds	99	105
Total restricted funds	(852)	(960)
Total funds held	(128)	(362)





The Board of Trustees



Angela Hosie

VIRTUAL

CONFERENCE



Robert Perkins



Kathy Jones
Treasurer



Gemma Fish



William Littleboy Chair



Carol McCudden



Barry Hunt Scientific Advisor



Harriet Brown



Rachel Harrison

